United States vs Uzbekistan: The number of people with susceptibility test result for rifampicin
United States
4,814
in 2021
Uzbekistan
4,929
in 2021
United States rank
30th
Uzbekistan rank
29th
The number of people with susceptibility test result for rifampicin over time
- United States
- Uzbekistan
How they compare
Uzbekistan currently reports 4,929 against 4,814 in United States, a difference of 115.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was United States ahead.
United States ranks 30th and Uzbekistan ranks 29th of 155 countries.
United States has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | United States | Uzbekistan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 5,218 | 4,839 | 379.33 | United States |
| 2020s | 4,592 | 4,438 | 154.5 | United States |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, United States or Uzbekistan?
- Uzbekistan, at 4,929 against 4,814 in United States as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between United States and Uzbekistan?
- 115, with Uzbekistan ahead.
- How many years of comparable data are there for United States and Uzbekistan?
- 5 years are reported by both, from 2017 to 2021.
- How do United States and Uzbekistan rank globally for the number of people with susceptibility test result for rifampicin?
- United States ranks 30th and Uzbekistan ranks 29th of 155 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients.. Statizoid refreshes it automatically from the source and publishes the full history for both places.